secwatch.observer — SEC 8-K summary
======================================

Issuer:     Equillium, Inc. (EQ)
CIK:        0001746466
Form:       8-K
Filed at:   2023-10-16T23:59:59+00:00
Accession:  0001193125-23-256538
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Equillium presents pre-clinical data for oral EQ302 targeting IL-15/IL-21; analysts day held
--------------------------------------------------------------------------------

- EQ302 is an orally deliverable multi-cytokine inhibitor targeting IL-15 and IL-21.
- Pre-clinical data show hydrocarbon staples improve GI stability while retaining cytokine inhibition.
- Oral EQ302 reduced IL-15-induced IFN-g transcription in mouse small intestine.
- Potential utility for Celiac Disease and inflammatory bowel disease highlighted.
- Analyst and investor day held October 16, 2023, with pipeline and platform update.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1746466/000119312523256538/0001193125-23-256538-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1746466/000119312523256538/d500418d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-256538

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer